Hollifield, Michael, Hsiao, An-Fu, Smith, Tyler, Calloway, Teresa, Jovanovic, Tanja, Smith, Besa, Carrick, Kala, Norrholm, Seth D., Munoz, Andrea, Alpert, Ruth, Caicedo, Brianna, Frousakis, Nikki, and Cocozza, Karen
Key Points: Question: Is verum acupuncture delivered over 12 to 15 weeks more efficacious than sham (minimal) needling for reducing posttraumatic stress disorder (PTSD) symptoms or fear-potentiated startle response in veterans with PTSD? Findings: In this randomized clinical trial including 93 participants, verum acupuncture resulted in a larger reduction in PTSD symptom severity than sham from the beginning to the end of treatment in both the intention-to-treat and treatment-completed models, and a larger reduction in fear-potentiated startle extinction after treatment. Meaning: The findings indicate that verum acupuncture had a large pretreatment to posttreatment effect and was clinically and statistically superior to sham needling for reducing PTSD symptoms and enhancing fear extinction. This randomized clinical trial assesses the effectiveness of verum vs sham acupuncture in reducing severity of symptoms in combat-related posttraumatic stress disorder. Importance: Current interventions for posttraumatic stress disorder (PTSD) are efficacious, yet effectiveness may be limited by adverse effects and high withdrawal rates. Acupuncture is an emerging intervention with positive preliminary data for PTSD. Objective: To compare verum acupuncture with sham acupuncture (minimal needling) on clinical and physiological outcomes. Design, Setting, and Participants: This was a 2-arm, parallel-group, prospective blinded randomized clinical trial hypothesizing superiority of verum to sham acupuncture. The study was conducted at a single outpatient-based site, the Tibor Rubin VA Medical Center in Long Beach, California, with recruitment from April 2018 to May 2022, followed by a 15-week treatment period. Following exclusion for characteristics that are known PTSD treatment confounds, might affect biological assessment, indicate past nonadherence or treatment resistance, or indicate risk of harm, 93 treatment-seeking combat veterans with PTSD aged 18 to 55 years were allocated to group by adaptive randomization and 71 participants completed the intervention protocols. Interventions: Verum and sham were provided as 1-hour sessions, twice weekly, and participants were given 15 weeks to complete up to 24 sessions. Main Outcomes and Measures: The primary outcome was pretreatment to posttreatment change in PTSD symptom severity on the Clinician-Administered PTSD Scale-5 (CAPS-5). The secondary outcome was pretreatment to posttreatment change in fear-conditioned extinction, assessed by fear-potentiated startle response. Outcomes were assessed at pretreatment, midtreatment, and posttreatment. General linear models comparing within- and between-group were analyzed in both intention-to-treat (ITT) and treatment-completed models. Results: A total of 85 male and 8 female veterans (mean [SD] age, 39.2 [8.5] years) were randomized. There was a large treatment effect of verum (Cohen d, 1.17), a moderate effect of sham (d, 0.67), and a moderate between-group effect favoring verum (mean [SD] Δ, 7.1 [11.8]; t90 = 2.87, d, 0.63; P =.005) in the intention-to-treat analysis. The effect pattern was similar in the treatment-completed analysis: verum d, 1.53; sham d, 0.86; between-group mean (SD) Δ, 7.4 (11.7); t69 = 2.64; d, 0.63; P =.01). There was a significant pretreatment to posttreatment reduction of fear-potentiated startle during extinction (ie, better fear extinction) in the verum but not the sham group and a significant correlation (r = 0.31) between symptom reduction and fear extinction. Withdrawal rates were low. Conclusions and Relevance: The acupuncture intervention used in this study was clinically efficacious and favorably affected the psychobiology of PTSD in combat veterans. These data build on extant literature and suggest that clinical implementation of acupuncture for PTSD, along with further research about comparative efficacy, durability, and mechanisms of effects, is warranted. Trial Registration: ClinicalTrials.gov Identifier: NCT02869646 [ABSTRACT FROM AUTHOR]